<div id="readability-page-1"><div>SAN DIEGO, May 15, 2026 /PRNewswire/ -- Robbins Geller Rudman &amp; Dowd LLP announces that purchasers or acquirers of Medpace Holdings Inc. () common stock between April 22, 2025 and February 9, 2026, both dates inclusive (the &#34;Class Period&#34;), have until Monday, June 8, 2026 to seek appointment as lead plaintiff of the Medpace class action lawsuit. Captioned Durbin v. Medpace Holdings Inc., No. 26-cv-00346 (S.D. Ohio), the Medpace class action lawsuit charges Medpace as well as certain of Medpace's top executives with violations of the Securities Exchange Act of 1934.If you suffered substantial losses and wish to serve as lead plaintiff of the Medpace class action lawsuit, please provide your information here:https://www.rgrdlaw.com/cases-medpace-holdings-inc-class-action-lawsuit-medp.htmlYou can also contact attorneys Ken Dolitsky or Michael Albert of Robbins Geller by calling 800/851-7783 or via e-mail at info@rgrdlaw.com.CASE ALLEGATIONS: Medpace is a clinical contract research organization (CRO) focused on providing scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries.The Medpace class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Medpace consistently oversold Medpace's projected book-to-bill ratio for fourth quarter 2025; (ii) Medpace knew or recklessly disregarded the impact that cancellations have on Medpace's book-to-bill ratio; (iii) Medpace frequently claimed that the projection of a 1.15 book-to-bill ratio for fourth quarter 2025 was reasonable and achievable and that cancellations were not a sign of a weak business environment; (iv) Medpace reassured investors that Medpace was not concerned about the lack of diversity in its pre-backlog; and (v) Medpace management stated that, despite the uptick in metabolic growth, Medpace's upside was broad-based and not isolated to any handful of studies.The Medpace class action lawsuit further alleges that on February 9, 2026, Medpace released fourth quarter 2025 earnings results revealing a book-to-bill ratio of 1.04, well below Medpace's guidance. On this news, the price of Medpace common stock fell nearly 16%, according to the complaint.THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Medpace common stock during the Class Period to seek appointment as lead plaintiff in the Medpace class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Medpace class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Medpace class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Medpace class action lawsuit.ABOUT ROBBINS GELLER: Robbins Geller Rudman &amp; Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder rights litigation. Our Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025. This marks our fourth #1 ranking in the past five years. And in those five years alone, Robbins Geller recovered $8.4 billion for investors – $3.4 billion more than any other law firm. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:https://www.rgrdlaw.com/services-litigation-securities-fraud.htmlPast results do not guarantee future outcomes.Services may be performed by attorneys in any of our offices.Contact:Robbins Geller Rudman &amp; Dowd LLPKen DolitskyMichael Albert655 W. Broadway, Suite 1900, San Diego, CA 92101800/851-7783info@rgrdlaw.comSOURCE Robbins Geller Rudman &amp; Dowd LLP</div></div>

Medpace控股

納斯達克生物科技指數 ETF - iShares Nasdaq

生物科技 ETF - VanEck Vectors

Robbins Geller Rudman & Dowd LLP 宣佈，受到損失的 Medpace Holdings Inc. 投資者可以在 2025 年 4 月 22 日至 2026 年 2 月 9 日期間，申請成為集體訴訟的主原告。該訴訟指控違反證券交易法，包括對公司賬單與收入比率的誤導性陳述。感興趣的投資者必須在 2026 年 6 月 8 日之前申請

INVESTOR NOTICE: Medpace Holdings Inc. (MEDP) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

PR Newswire

動態生物技術與基因組 ETF - Invesco

紐交所高增長板生物技術指數 ETF - First Trust

2 倍做多納斯達克生物技術 ETF - ProShares

基因免疫&健康關懷 ETF - iShares

基因改革 ETF - ARK

標普生物技術 ETF - SPDR

標普生物技術 3 倍做多 - Direxion

醫藥突破 ETF - ALPS

投資者通知：Medpace 控股公司（MEDP）遭受重大損失的投資者有機會主導集體訴訟